Clinician Recommendation for Hereditary Genetic Testing in Participants at Increased Risk for Hereditary Cancer
Open Access
Abstract
Background: Despite clinical utility in managing hereditary cancers, genetic testing (GT) remains underutilized. While barriers include knowledge gaps and cost, clinician recommendation is a major driver of GT uptake, with rates varying by cancer type and family cancer history documentation. Methods: Adult participants (≥18 years) were recruited through multiple sources to complete a cancer family history survey for a larger intervention trial. Participants with personal or family history indicating increased hereditary cancer risk who had not undergone GT (N = 3001) were invited to complete a baseline survey. Multivariable logistic regression was used to analyze associations between demographics and cancer history by receipt of a clinician recommendation for GT. Results: Among 784 respondents, most were White (84.6%), female (58.4%), and over age 51 (75.3%), with 58.2% reporting a diagnosis of cancer. Only 14.0% reported receiving a clinician recommendation for GT, with lower recommendation rates among younger adults (20.1%), those reporting no financial stress (10.7%), and those with higher education (12.0%). Multivariate analysis showed participants who did not report financial stress (p = 0.049) were less likely to receive a recommendation. Discussion: These findings highlight disparities in GT recommendation by clinicians. Increased clinician education about indications for GT, the implementation of electronic medical record tools to facilitate the identification of patients with guideline-concordant personal and/or biological-relative cancer history, and patient-facing interventions could standardize the dissemination of recommendations for GT. Conclusions: Future efforts that focus on increasing clinician education and electronic decision support should identify individuals with personal and/or biological-relative cancer history meeting criteria for GT.Keywords
Funding Information
- National Institutes of Health (U01CA232827)
- mPIs Stoffel, Griggs, and Resnicow (U01CA232827)
This publication has 24 references indexed in Scilit:
- Interventions to improve delivery of cancer genetics services in the United States: A scoping reviewGenetics in Medicine, 2022
- Recall of Genomic Testing Results Among Patients with CancerThe Oncologist, 2021
- Barriers and facilitators of germline genetic evaluation for prostate cancerThe Prostate, 2021
- “I think that a brief conversation from their provider can go a very long way”: Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancerSupportive Care in Cancer, 2020
- Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendationsCancer, 2019
- Patients' willingness to reconsider cancer genetic testing after initially declining: Mention it againJournal of Genetic Counseling, 2019
- Low Referral Rate for Genetic Testing in Racially and Ethnically Diverse Patients Despite Universal Colorectal Cancer ScreeningClinical Gastroenterology and Hepatology, 2018
- Interpretations of the Term “Actionable” when Discussing Genetic Test Results: What you Mean Is Not What I HeardJournal of Genetic Counseling, 2018
- Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancerBreast Cancer Research and Treatment, 2015
- Uptake of Genetic Testing by Relatives of Lynch Syndrome Probands: A Systematic ReviewClinical Gastroenterology and Hepatology, 2013